ASGCT Late Breakers: Pfizer’s Duchenne Results Underwhelm As Next-Gen Approaches Emerge
Sarepta Set For Landmark Approval
Executive Summary
The congress’s late breakers highlight progress across cell and gene platforms and diseases, and Duchenne is in the spotlight as Sarepta’s SRP-9001 could soon gain accelerated approval.
You may also be interested in...
Slim Adcomm Majority Boosts Sarepta’s Gene Therapy In Duchenne Muscular Dystrophy
Accelerated approval seems imminent after a majority of the US FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted the risk-benefit balance supported it.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.
Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.